Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF cells for post-COVID-19 pulmonary fibrosis
NCT06304623Phase 1Completed
- Start
- May 2020
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose-derived stromal vascular fraction in pulmonary fibrosis (PF). Primary endpoint: Safety of treatment with SVF IV at 12 months. Started May 2020; status: completed.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06304623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304623.